GeorgeRSimonMD

Executive Medical Director and Dept. Chair Moffitt-AdventHealth Joint Clinical Research Unit Professor of Medicine and Oncology H Lee Moffitt Cancer Center & USF Morsani School of Medicine

Join to view full profile

Dr. Simon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Simon's full profile

Already have an account?

Office
380 Celebration Pl
2nd FL
Celebration, FL 34747
Phone+1 407-303-4078

Fax+1 407-303-4803
Is this information wrong?

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 1992 - 1997
Saint Joseph HospitalResidency, Internal Medicine, 1993 - 1995
Christian Medical College LudhianaClass of 1986

Certifications & Licensure

FL State Medical License 2000 - 2026
TX State Medical License 2012 - 2021
OK State Medical License 2020 - 2021
SC State Medical License 2010 - 2013
PA State Medical License 2008 - 2010
CO State Medical License 1997 - 2009
AZ State Medical License 1997 - 1998

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Fellow (FACP) American College of Physicians, 2001
Join now to see all

Clinical Trials

Trial of Poor Performance Status Patients (ToPPS) Start of enrollment: 2009 Jun 01
Completed
Phase 2
Cisplatin and Pemetrexed With Radiation Followed by Lobectomy Start of enrollment: 2011 May 01
Terminated
Phase 1
A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2012 Jan 01
Withdrawn
Phase 2

Publications & Presentations

PubMed

Osimertinibafatinib as first-line treatment for patients with metastatic non-small cell lung cancer with anexon 19 deletion or exon 21 L858R mutation.
Gilardone, S., Thapa, R., Laborde, J., Chen, D., Melzer, D., Pellini, B., Shafique, M., Saltos, A., Creelan, B., Tanvetyanon, T., Chiappori, A., Simon, G., Haura, E., ...> ;Journal of Thoracic Disease. 2023 Nov 30
Perspective: rethinking therapeutic strategies in oncology.
Patz, E., Gottlin, E., Simon, G.> ;Frontiers in Oncology. 2023 Jan 1
3 citations
A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous N...
Sarina Piha-Paul, George Simon, Chandra P Belani, Heman Chao, Kim Gaspar, Brenda Lee, Afshin Dowlati> ;JTO Clinical and Research Reports. 2022 Nov 1
10 citations
Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
Whitney E. Lewis, Lingzhi Hong, Frank E. Mott, George R. Simon, Carol C. Wu, Waree Rinsurongkawong, J. Jack Lee, Vincent K. Lam, John V. Heymach, Jianjun Zhang, Xiunin...> ;JTO Clinical and Research Reports. 2021 Oct 9
2 citations
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping
Marissa N. Lawrence, Rubii M. Tamen, Pablo Martinez, Alicia Sable-Hunt, Tony Addario, Pete Barbour, Tristan Shaffer, Seyed Ali Hosseini, Caterina Bertucci, Lee P. Lim,...> ;JTO Clinical and Research Reports. 2021 Apr 1
40 citations
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC.
James W. Welsh, John V. Heymach, Chunxiao Guo, Hari Menon, Katherine Klein, Taylor R. Cushman, Vivek Verma, Kenneth R. Hess, Girish S. Shroff, Chad Tang, Ferdinandos S...> ;Journal of Thoracic Oncology. 2020 Dec 1
234 citations
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Willemijn S. M. E. Theelen, Dawei Chen, Vivek Verma, Brian P. Hobbs, Heike Peulen, Joachim G.J.V. Aerts, Idris Bahce, Anna Larissa N. Niemeijer, Joe Y. Chang, Patricia...> ;The Lancet. Respiratory Medicine. 2021 May 1
120 citations
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
James W. Welsh, Hari Menon, Dawei Chen, Vivek Verma, Chad Tang, Mehmet Altan, Kenneth R. Hess, Patricia M. de Groot, Quynh-Nhu Nguyen, Rejani Varghese, Nathan Comeaux,...> ;Journal for Immunotherapy of Cancer. 2020 Oct 1
7 citations
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Yanhong Zhou, J. Jack Lee, Xi Ming Tang, Wei Lu, Ignacio I. Wistuba, Renata Ferrarotto, Don L. Gibbons, Bonnie S. Glisson, Merrill S. Kies, George R. Simon, John V. He...> ;The Oncologist. 2020 Oct 1
41 citations
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Aparna Hegde, Alexander Y. Andreev-Drakhlin, Jason Roszik, Le Huang, Shuang Liu, Kenneth R. Hess, Maria E. Cabanillas, Mimi I. Hu, Naifa L. Busaidy, Steven I. Sherman,...> ;ESMO Open. 2020 Jan 1
83 citations
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
Lingzhi Hong, Marcelo V. Negrao, Seyedeh Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M. Bohac, Xiaoke Liu, Ferdinandos Skoulidis, Tina Cascone, Kyle G. Mitchell, Hai T....> ;Journal of Thoracic Oncology. 2020 Sep 1
7 citations
What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer.
Meagan Whisenant, Loretta A. Williams, Araceli Garcia Gonzalez, Tito R. Mendoza, Qiuling Shi, Charles S. Cleeland, Jianjun Zhang, John V. Heymach, George R. Simon> ;JCO Oncology Practice. 2020 Jun 15
20 citations
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.
Tina Cascone, Boris Sepesi, Heather Lin, Neda Kalhor, Edwin R. Parra, Mei Jiang, Myrna C.B. Godoy, Jianjun Zhang, Frank V. Fossella, Anne S. Tsao, Vincent K. Lam, Char...> ;Clinical Cancer Research. 2020 Mar 19
77 citations
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC.
Steven H. Lin, Yan Lin, Luyang Yao, Neda Kalhor, Brett W. Carter, Mehmet Altan, George R. Blumenschein, Lauren Averett Byers, Frank V. Fossella, Don L. Gibbons, Jonath...> ;Journal of Thoracic Oncology. 2020 Feb 1
52 citations
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer
James W. Welsh, John V. Heymach, Dawei Chen, Vivek Verma, Taylor R. Cushman, Kenneth R. Hess, Girish S. Shroff, Chad Tang, Ferdinandos Skoulidis, Melenda Jeter, Hari M...> ;Journal of Thoracic Oncology. 2020 Feb 1
74 citations
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses
James W. Welsh, Chad Tang, Patricia M. de Groot, Aung Naing, Kenneth R. Hess, John V. Heymach, Vassiliki A. Papadimitrakopoulou, Taylor R. Cushman, Vivek Subbiah, Joe ...> ;Cancer Immunology Research. 2019 Oct 28
8 citations
Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non‐small cell lung cancer
Bin Shi, Carmen Behrens, Viralkumar Vaghani, Erick Riquelme, Jaime Rodriguez-Canales, Humam Kadara, Heather Lin, Hui Liu, Ignacio I. Wistuba, George R. Simon> ;Cancer Medicine. 2019 Aug 27
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 1...
Hossein Maymani, Kenneth R. Hess, Roman Groisberg, David S. Hong, Aung Naing, Sarina Anne Piha-Paul, Filip Janku, Siqing Fu, Apostolia Maria Tsimberidou, Shubham Pant,...> ;Lung Cancer. 2019 Aug 21
27 citations
Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care
George R. Simon, Courtney D. DiNardo, Koichi Takahashi, Tina Cascone, Cynthia A. Powers, Rick Stevens, Joshua S. Allen, Mara B. Antonoff, Daniel R. Gomez, Pat Keane, F...> ;The Oncologist. 2019 Jun 1
36 citations
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recur...
Alberto Chiappori, Charles C. Williams, Jhanelle E. Gray, Tawee Tanvetyanon, Eric B. Haura, Ben C. Creelan, Ram Thapa, Dung-Tsa Chen, George R. Simon, Gerold Bepler, D...> ;Cancer Immunology, Immunotherapy. 2019 Mar 1
41 citations
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.
Andrew Frederickson, Stella Arndorfer, Ina Zhang, Maria Lorenzi, Ralph P. Insinga, Ashwini Arunachalam, Thomas Burke, George R. Simon> ;Immunotherapy. 2019 Feb 4
33 citations
Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study
Tito R. Mendoza, Kenneth L. Kehl, Oluwatosin Bamidele, Loretta A. Williams, Qiuling Shi, Charles S. Cleeland, George R. Simon> ;Supportive Care in Cancer. 2019 Jan 19
14 citations
Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)
Fred R. Hirsch, Lecia V. Sequist, Ira Gore, Meghan J. Mooradian, George R. Simon, Elisabeth Croft, Diana Devincenzo, Jiefen Munley, Dara Stein, Klaus Freivogel, Frangi...> ;Cancer. 2018 Jun 1
27 citations
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials
Hossein Maymani, Kenneth R. Hess, Roman Groisberg, David S. Hong, Aung Naing, Sarina Anne Piha-Paul, Filip Janku, Siqing Fu, Apostolia Maria Tsimberidou, Shubham Pant,...> ;Lung Cancer. 2018 Jun 1
24 citations
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations
Neeta Somaiah, Hannah C. Beird, Andrea G. Barbo, Juhee Song, Kenna R. Mills Shaw, Wei Lien Wang, Karina Eterovic, Ken Chen, Alexander J. Lazar, Anthony P. Conley, Vino...> ;Oncotarget. 2018 Apr 13
Join now to see all

Press Mentions

Mesothelioma Treatment Program Expanding in Central FloridaSeptember 8th, 2021
Onc.AI Raises $6M Financing Round Co-Led by Blue Venture Fund and AccompliceDecember 3rd, 2020
Delivering a Cancer-Free Frontier During COVID-19September 4th, 2020
Join now to see all